We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

MorphoSys's Partner Heptares Initiates Proprietary Therapeutic Antibody Program

News   Aug 06, 2015

 
MorphoSys's Partner Heptares Initiates Proprietary Therapeutic Antibody Program
 
 
 

RELATED ARTICLES

A Potential Drug Target for Diabetic Retinopathy

News

Approximately one in three diabetic patients develops diabetic retinopathy (DR), which can cause visual impairment and eventual blindness. Now researchers have discovered that high glucose increases the levels of enzymatic precursor, called lysyl oxidase propeptide (LOX-PP), that promotes cell death which could be a potential target for treating DR.

READ MORE

Team Discover Protein That Hampers Bone Healing

News

Scientists have discovered that a certain protein, which is more prevalent in older people, interferes with bone healing.

READ MORE

New Study of HIV Vaccine Shows Promising Results Across Strains

News

Using the same RV 144 HIV vaccine employed in Thailand, a new study has evaluated whether the vaccine-induced immune responses to RV 144 are similar in a South African cohort.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE